George Washington School

Davis Wright Tremaine Names Julia Bennett Chief Marketing and Business Development Officer

Retrieved on: 
Monday, February 5, 2024
Professional Services, Marketing, Communications, Legal, Consulting, Other Communications, Williams Mullen, Shearman & Sterling, Multimedia, University, Crowell & Moring, Duke University, George Washington School, Shearman

Davis Wright Tremaine has named Julia Bennett as its new chief marketing and business development officer.

Key Points: 
  • Davis Wright Tremaine has named Julia Bennett as its new chief marketing and business development officer.
  • Bennett, who will be based in the firm’s Washington, D.C., office, brings nearly two decades of experience in the legal industry, having led the marketing and business development functions in law firms as well as practiced as a lawyer.
  • “She will play a major role in helping Davis Wright continue to strengthen our brand within our core markets, practices, and industry verticals.”
    Bennett joins Davis Wright after serving as the first-ever chief marketing officer of Brown Rudnick, where she led the business development and marketing communications functions of the firm in the U.S. and U.K.
  • Previously, she served as the senior director of business development at Venable and worked in marketing and business development at Williams Mullen.

AVEO Oncology Enrolls First Patient in Pivotal FIERCE-HN Clinical Trial to Evaluate Ficlatuzumab in Combination with ERBITUX® (cetuximab) in Patients with HPV-negative Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

Retrieved on: 
Tuesday, January 16, 2024
Ficlatuzumab, Patient, Outline of health sciences, HGF, HNSCC, Survival, Cetuximab, Medicine, Cancer, George Washington School, Optimism, Food, Hepatocyte growth factor, Fast Track, HPV, LG Chem, MPH

BOSTON, Jan. 16, 2024 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”), an LG Chem company, today announced enrollment of the first patient in the FIERCE-HN trial, a global, multicenter, randomized, double-blind, placebo-controlled, phase 3 clinical trial evaluating ficlatuzumab in combination with ERBITUX® (cetuximab), an anti-EGFR antibody, in patients with human papillomavirus (HPV)-negative recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).

Key Points: 
  • BOSTON, Jan. 16, 2024 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”), an LG Chem company, today announced enrollment of the first patient in the FIERCE-HN trial, a global, multicenter, randomized, double-blind, placebo-controlled, phase 3 clinical trial evaluating ficlatuzumab in combination with ERBITUX® (cetuximab), an anti-EGFR antibody, in patients with human papillomavirus (HPV)-negative recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).
  • Ficlatuzumab is AVEO’s investigational antibody that targets hepatocyte growth factor (HGF).
  • That designation followed AVEO’s June 2021 announcement of positive results from a randomized phase 2 study of ficlatuzumab alone or in combination with cetuximab in patients with pan-refractory, metastatic HNSCC.
  • “We therefore approach the FIERCE-HN trial with a mix of urgency and optimism, as the combination of ficlatuzumab and cetuximab has the potential to expand the range of viable therapeutic options for this underserved population.”

Onconova Expands Leadership Team with Two Key Appointments

Retrieved on: 
Tuesday, October 24, 2023
Drug development, Research, Bone marrow, Ovarian cancer, Nottingham Trent University, Medicine, Internal medicine, Bachelor, Biomedical sciences, George Washington School, Pediatric Hematology and Oncology, Medical Affairs Bureau, Pharmacy, European Society for Clinical Investigation, Pharmaceutical medicine, University of Zimbabwe, Postgraduate diploma, Epidermolysis bullosa, University, NDA, Cancer, Therapy, Patient, Myelodysplastic syndrome, Merrimack Pharmaceuticals, GSK plc, Medication, CMO, Nottingham, Johns Hopkins School of Medicine, King's College London, University of Surrey, IND, Consultant, Outline of health sciences, Patent, Rare, Inflammation, R, EB, Johnson & Johnson, Pharmaceutical industry, Nursing, Biotechnology, Science, Hematology, Honours degree

NEWTOWN, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company expanded its leadership team with the naming of Dr. Victor Moyo as Chief Medical Officer (CMO), and the addition of Meena Arora as Vice President, Global Medical Affairs and Research and Development (R&D).

Key Points: 
  • Both are accomplished experts in their fields and bring significant and wide expertise in drug development.
  • I look forward to working with my colleagues at Onconova and our clinical collaborators to contribute to our mission of bringing narazaciclib and rigosertib to patients with cancer.
  • He has also held various leadership roles as Vice President of Clinical Investigations at Merrimack Pharmaceuticals and the Centocor Ortho Biotech Services, LLC division of Johnson & Johnson.
  • Prior to that, she held various leadership roles as Medical Director or Associate Medical Director, as well as roles in Investigator Research and Medical Affairs at Celgene International.

Honor the Gift disputes CMS' claim that there is no change in Medicare coverage of blood tests for monitoring rejection in transplant patients

Retrieved on: 
Wednesday, September 27, 2023
Centers for Medicare & Medicaid Services, DNA, Gift, CMS, Honor walk, Rush University Medical Center, The Wall Street Journal, International Society for Heart and Lung Transplantation, Anxiety, Lung transplantation, Patient, Policy, International Society of Sculptors, Painters and Gravers, American Society of Transplantation, Health equity, Multimedia, Transplant, LCD, Associate, Government, George Washington University Hospital, Dialysis, Medicare, Congress, George Washington School, Medical director, Physician, Organ transplantation, Division, Democrat, Surgeon, Kidney, George Washington University School of Medicine & Health Sciences, Health, Longevity, House, Society, Macs, Biopsy, Transplant surgeon, Hospital, Pharmaceutical industry, Dentistry, MD

WASHINGTON, Sept. 27, 2023 /PRNewswire/ -- Honor the Gift, a coalition representing organ transplant patients across the nation, along with other allied leaders across the transplant field, respond to the Centers for Medicare & Medicaid Services' (CMS) press release stating that "neither CMS nor the Medicare Administrative Contractors (MACs) have made changes that affect patients' ability to have blood tests used to monitor for organ transplantation rejection covered when ordered by their physicians in medically appropriate circumstances."  

Key Points: 
  • The Honor the Gift coalition finds this statement inaccurate and contradicted by patients and physicians nationwide.
  • The changes announced on March 2, 2023, have alarmed transplant patients and clinicians across the nation, followed by an apparent decline in physician ordering of these vital blood tests1.
  • The Honor the Gift coalition and allies dispute this assertion – this is not a "clarification" but a change in coverage policy.
  • The concerns raised by patients, clinicians, and Congress emphasize the need for continued dialogue to restore longstanding Medicare coverage.

ICER MIDWEST CEPAC WORKS TO KEEP UP WITH WELL-INFORMED NASH PATIENT ADVOCATES

Retrieved on: 
Monday, May 1, 2023
Institute for Clinical and Economic Review, Insurance, Medicaid, NASH, Education, GLI, Fatty liver disease, Obeticholic acid, Weight loss, Special, Hepatic encephalopathy, Human, Bangladesh Technical Education Board, Hepatitis, George Washington School, Public health, HIV disease progression rates, Patient, JD, OCA, Milken Institute, ICER, Knowledge, Liver, NAFLD, Policy, FDA, JAMA, Pharmaceutical industry, Midwestern United States

ICER's voting questions and assumptions failed to reflect the complexities of the NASH patient experience.

Key Points: 
  • ICER's voting questions and assumptions failed to reflect the complexities of the NASH patient experience.
  • NASH Patients’ 5 top takeaways from the ICER Meeting:
    “We’re not brand new” - NASH patient Kimberly Martinez emphatically stated to ICER Policy Roundtable members.
  • Cardiovascular side effects were weighed heavily by members of the Midwest CEPAC, even if those effects were manageable by statins and for an uncertain duration.
  • Few Midwest CEPAC members voted to recognize caregiver impact despite NASH patient caregiver, support group leader, and co-founder of NASH KNOWLEDGE, Betsy Villotti’s stirring testimony that families are “being held hostage by liver disease” as their loved one descended into hepatic encephalopathy and other NASH complications.

PATIENT GROUPS DECLARE ICER REVIEW OF NASH MEDICATIONS CAUSES MORE UNCERTAINTY AND CONTROVERSIES THAN IT RESOLVES

Retrieved on: 
Friday, April 28, 2023
Institute for Clinical and Economic Review, NASH, Education, GLI, Fatty liver disease, LAN, Obeticholic acid, Policy, Non-alcoholic fatty liver disease, Cancer, Quality of life, Scar, Research, CEPAC, Inflammation, Bangladesh Technical Education Board, Diagnosis, Fibrosis, George Washington School, Public health, HIV disease progression rates, Patient, Swelling, Milken Institute, Drug development, ICER, Liver, NAFLD, Chronic liver disease, Health, FDA, Death, Cirrhosis, Disease, Medical device, Dietary supplement, EU

NAFLD is a chronic progressive condition of which NASH is the more advanced form, where the extra fat turns into inflammation (swelling) and fibrosis (scarring) of the liver.

Key Points: 
  • NAFLD is a chronic progressive condition of which NASH is the more advanced form, where the extra fat turns into inflammation (swelling) and fibrosis (scarring) of the liver.
  • If severe enough, NASH can lead to cirrhosis, cancer, the need for a transplant, or death.
  • Donna Cryer, President & CEO of Global Liver Institute and 28-year liver transplant survivor said, “NASH is a chronic, progressive illness.
  • GLI calls on ICER to take these patient experiences seriously in its evaluation in the final assessment of resmetirom and obeticholic acid for the treatment of NASH.

American College of Lifestyle Medicine's Health Equity Initiative Expands Priorities to Include Federally Qualified Health Centers

Retrieved on: 
Thursday, March 30, 2023
CME, Workforce, Obesity, Lifestyle medicine, Pediatrics, Initiative, Health equity, St. Cloud VA Health Care System, Type 2 diabetes, Innovation, MBA, Medicine, Essential, Child, Health system, Doctor of Philosophy, Howard University College of Medicine, Harvard Medical School, DNP, UIM, Federally Qualified Health Center, ACLM, Liaquat National Hospital, George Washington School, Children's National Hospital, White House conference, Patient, Risk, Physician, Outline of health sciences, Faculty, HEAL, American College, Health, Food, Conference, Community, Conditional sentence, Pharmaceutical industry, Nursing, Management, FAAP, MD, Hunger, MPH

ST. LOUIS, March 30, 2023 /PRNewswire-PRWeb/ -- The American College of Lifestyle Medicine's (ACLM) HEAL (Health Equity Achieved through Lifestyle Medicine) Initiative announced today an additional strategic priority to continue addressing the needs of historically underserved groups that are at a higher risk for chronic disease. Effective April 1, 2023, HEAL leadership will add a focus on integrating lifestyle medicine into Federally Qualified Health Centers (FQHCs) and Community Health Centers (CHCs).

Key Points: 
  • ST. LOUIS, March 30, 2023 /PRNewswire-PRWeb/ -- The American College of Lifestyle Medicine's (ACLM) HEAL (Health Equity Achieved through Lifestyle Medicine) Initiative announced today an additional strategic priority to continue addressing the needs of historically underserved groups that are at a higher risk for chronic disease.
  • Effective April 1, 2023, HEAL leadership will add a focus on integrating lifestyle medicine into Federally Qualified Health Centers (FQHCs) and Community Health Centers (CHCs).
  • An important element of this new strategy is ACLM's 5.5-hour CME/CE-accredited complimentary course, "Introduction to Lifestyle Medicine & Food as Medicine Essentials" course bundle.
  • Each leader has laudable experience and has demonstrated their passion for health equity and lifestyle medicine.

As Nation’s Obesity Epidemic Continues to Rise, Physicians Slam USDA for $21.9 Million Effort to Market Meat to Americans

Retrieved on: 
Friday, September 2, 2022
Other Policy Issues, Women, Seniors, Other Science, Research, Men, Other Retail, General Health, Family, Public Policy, Government, Consumer, Food, Beverage, Retail, Healthcare Reform, Health, White House, Federal Government, State, Local, Supply Chain Management, Other Consumer, Science, Public Policy, Physicians Committee for Responsible Medicine, Office of Inspector General, U.S. Department of Health and Human Services, Dairy, Nutrition, Obesity, Vegetable, White House conference, Conditional sentence, USDA, Poultry, Policy, Physician, Health, George Washington School, Farmer, Goal, MD, Medicine, FACC, Conference, Hypertension, U.S. Department of Agriculture Cotton Annex, Meat, Nursing, Risk, Diabetes, Firefighter, Industry, Marketing, Adoption, Pharmaceutical industry, Hunger

This announcement comes on the eve of the White House Conference on Hunger, Nutrition, and Health on Sept. 28.

Key Points: 
  • This announcement comes on the eve of the White House Conference on Hunger, Nutrition, and Health on Sept. 28.
  • The conference looks toward ending hunger and increasing healthy eating so that fewer Americans experience diet-related diseases like diabetes, obesity, and hypertension.
  • This is a clear case of the one hand not knowing what the other hand is doing, Dr. Barnard says.
  • The Physicians Committee recommends that members of the White House Conference act to ensure the implementation of four essential policy goals:

Concentric Energy Advisors Announces the Appointment of Michael Kagan to the Board of Directors

Retrieved on: 
Tuesday, February 15, 2022
Constellation, Mark (given name), AES Corporation, Exelon, Business, AES, Concentric objects, Leadership, Regents of the University of California, Director, Skidmore College, Board, Senior, Economics, George Washington School, University, Management

Marlborough, Mass., Feb. 14, 2022 /PRNewswire/ --Concentric Energy Advisors, Inc. (Concentric), a leading management consulting and financial advisory services firm focusing on the North American energy and water industries, announced today the appointment of Michael Kagan , Senior Vice President, to the Board of Directors.

Key Points: 
  • Marlborough, Mass., Feb. 14, 2022 /PRNewswire/ --Concentric Energy Advisors, Inc. (Concentric), a leading management consulting and financial advisory services firm focusing on the North American energy and water industries, announced today the appointment of Michael Kagan , Senior Vice President, to the Board of Directors.
  • "I am proud to welcome Michael to the Board of Directors," said John J. Reed, Chairman of the Board and Chief Executive Officer of Concentric.
  • Concentric Energy Advisors specializes in management consulting and financial advisory services focusing on the North American energy and water industries.
  • In addition, through its subsidiaries, CE Capital Advisors and Concentric Advisors ULC, Concentric provides capital market advisory support and consulting services in Canada.

America's Largest Kidney Patient Group Opens Nominations for Medal of Excellence

Retrieved on: 
Thursday, August 12, 2021
Master of Science, DO, Patient, Kidney failure, Partnership, International Design Excellence Awards, Research, Doctor of Philosophy, Kidney disease, Office of Inspector General, U.S. Department of Health and Human Services, FACP, Association, Family and Medical Leave Act of 1993, Time, FASN, Dialysis, MS, Awareness, Criterion, COVID, Health education, American Association, Human, Facebook, Social media, RN, Policy, White House, George Washington School, Kidney, U.S. Department of Labor, Office of Inspector General, Goal, CNN, Transplant, FAAN, Nephrology, CMS, Congress, ESRD, MSN, Disease, FMLA, Transplant surgeon, Program, Twitter, USMC, Coronavirus, Chronic kidney disease, End Stage Renal Disease Program, Advancing American Kidney Health, Pharmaceutical industry, Medicine

WASHINGTON, Aug. 12, 2021 /PRNewswire/ -- The American Association of Kidney Patients (AAKP), the largest kidney patient organization in America, is now accepting nominations for its 2022 Medal of Excellence Award.

Key Points: 
  • WASHINGTON, Aug. 12, 2021 /PRNewswire/ -- The American Association of Kidney Patients (AAKP), the largest kidney patient organization in America, is now accepting nominations for its 2022 Medal of Excellence Award.
  • The AAKP Medal of Excellence Program recognizes renal healthcare professionals in seven categories: Physician, Transplant Surgeon, Transplant Professional, Nurse, Social Worker, Dietitian, and Dialysis Technician.
  • Founded in 1969, AAKP is the oldest kidney patient organization in America and a national and international voice and organizer for transplant patients, organ donors, dialysis patients, and those suffering from chronic kidney disease.
  • About the American Association of Kidney Patients (AAKP):Founded in 1969, AAKP is the largest kidney patient organization driving policy discussions on kidney patient consumer care choice and treatment innovations.